Focus: Iambic Therapeutics is an AI-driven drug discovery company founded in 2023, focused on oncology, neurology, and gastroenterology. The company is pre-revenue and early-stage with a single Phase 1 program in HER2-mutant tumors.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
10 added, 9 removed. Backfill posture.
Iambic is a high-risk, high-reward early-stage bet suited for career builders comfortable with startup volatility and seeking to shape an AI-biotech platform from inception.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Iambic Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Iambic Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Iambic, Takeda Ink $1.7B Deal - San Diego Business Journal
Iambic, Takeda Ink $1.7B Deal San Diego Business Journal
Lundbeck steps up its focus on AI: "Every project will benefit" - medwatch.com
Lundbeck steps up its focus on AI: "Every project will benefit" medwatch.com
Fierce Pharma Asia—Lilly, Innovent go 'beyond traditional licensing'; China indicts AZ; Madrigal inks siRNA deal - Fierce Pharma
Fierce Pharma Asia—Lilly, Innovent go 'beyond traditional licensing'; China indicts AZ; Madrigal inks siRNA deal Fierce Pharma
Feb. 10 Business Watch: Biotech IPOs are back; FMC may soon be for sale - C&EN
Feb. 10 Business Watch: Biotech IPOs are back; FMC may soon be for sale C&EN
Takeda signs $1.7bn AI alliance with Iambic - pharmaphorum
Takeda signs $1.7bn AI alliance with Iambic pharmaphorum
Takeda inks $1.7B AI discovery deal with Iambic Therapeutics - Fierce Biotech
Takeda inks $1.7B AI discovery deal with Iambic Therapeutics Fierce Biotech
Showing 6 of 10 news items
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo